Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban versus enoxaparin for postoperative venous thromboembolism prevention after gynecologic cancer surgery
IRCT20141231020504N2Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in venous thromboembolism (VTE) comparing Apixaban arm with Enoxaparin control arm (2 arms). Primary endpoint: Incidence of major bleeding or clinically relevant non-major bleeding. Started May 2023; status: completed.
02
Drugs
apixabanenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on IRCT20141231020504N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141231020504N2.